Compile Data Set for Download or QSAR
Report error Found 180 Enz. Inhib. hit(s) with all data for entry = 11642
TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636432(US20230365554, Example 1 | N-{4-[3-anilino-7-ethyl...)
Affinity DataIC50: 1.5nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636473(US20230365554, Example 42 | N-{4-[3-anilino-7-(2,2...)
Affinity DataIC50: 1.80nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636456((+)-(2R or S)—N-{4-[cis-3-anilino-4-oxo-1,4,5...)
Affinity DataIC50: 2.30nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636437(N-{4-[3-anilino-5,7-dimethyl-4-oxo-4,5,6,7-tetrahy...)
Affinity DataIC50: 2.60nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636473(US20230365554, Example 42 | N-{4-[3-anilino-7-(2,2...)
Affinity DataIC50: 2.80nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 3nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636456((+)-(2R or S)—N-{4-[cis-3-anilino-4-oxo-1,4,5...)
Affinity DataIC50: 3.10nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636445(US20230365554, Example 14 | US20230365554, Example...)
Affinity DataIC50: 3.10nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636432(US20230365554, Example 1 | N-{4-[3-anilino-7-ethyl...)
Affinity DataIC50: 3.30nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636473(US20230365554, Example 42 | N-{4-[3-anilino-7-(2,2...)
Affinity DataIC50: 3.30nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636477(US20230365554, Example 46 | US20230365554, Example...)
Affinity DataIC50: 3.40nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636459(US20230365554, Example 28 | US20230365554, Example...)
Affinity DataIC50: 3.70nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636432(US20230365554, Example 1 | N-{4-[3-anilino-7-ethyl...)
Affinity DataIC50: 3.80nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636449(US20230365554, Example 18 | US20230365554, Example...)
Affinity DataIC50: 3.90nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 4nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636473(US20230365554, Example 42 | N-{4-[3-anilino-7-(2,2...)
Affinity DataIC50: 4.10nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636469(N-[4-(3-anilino-5,7-dimethyl-4-oxo-4,5-dihydro-1H-...)
Affinity DataIC50: 4.20nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636465(N-{4-[3-anilino-5-methyl-4-oxo-7-(2,2,2-trifluoroe...)
Affinity DataIC50: 4.30nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636473(US20230365554, Example 42 | N-{4-[3-anilino-7-(2,2...)
Affinity DataIC50: 4.30nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636445(US20230365554, Example 14 | US20230365554, Example...)
Affinity DataIC50: 4.30nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM415424(US10428063, Example 24 | N-{4-[5-methyl-4-oxo-3-(p...)
Affinity DataIC50: 4.51nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636480(US20230365554, Example 49 | N-{4-[(7RS)-7-(cyclopr...)
Affinity DataIC50: 5.10nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636445(US20230365554, Example 14 | US20230365554, Example...)
Affinity DataIC50: 5.10nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636432(US20230365554, Example 1 | N-{4-[3-anilino-7-ethyl...)
Affinity DataIC50: 5.20nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636459(US20230365554, Example 28 | US20230365554, Example...)
Affinity DataIC50: 5.20nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636441(N-{4-[3-anilino-5,7-dimethyl-4-oxo-4,5,6,7-tetrahy...)
Affinity DataIC50: 5.40nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636453((+)-(2R or S)—N-{4-[cis-3-anilino-4-oxo-1,4,5...)
Affinity DataIC50: 5.40nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636432(US20230365554, Example 1 | N-{4-[3-anilino-7-ethyl...)
Affinity DataIC50: 5.5nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636438((−)-N-{4-[3-anilino-5,7-dimethyl-4-oxo-4,5,6...)
Affinity DataIC50: 5.5nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636440(N-{4-[(7RS)-3-anilino-5,7-dimethyl-4-oxo-4,5,6,7-t...)
Affinity DataIC50: 5.60nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636476(N-{4-[3-anilino-7-(2,2-difluoroethyl)-5-methyl-4-o...)
Affinity DataIC50: 5.70nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636457((2S)—N-[4-(3-anilino-5-methyl-4-oxo-4,5-dihyd...)
Affinity DataIC50: 5.90nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636466(US20230365554, Example 35 | US20230365554, Example...)
Affinity DataIC50: 5.90nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636480(US20230365554, Example 49 | N-{4-[(7RS)-7-(cyclopr...)
Affinity DataIC50: 5.90nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636473(US20230365554, Example 42 | N-{4-[3-anilino-7-(2,2...)
Affinity DataIC50: 5.90nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636464(2-(4-fluorophenyl)-N-{4-[5-methyl-3-(2-methylanili...)
Affinity DataIC50: 6.20nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636466(US20230365554, Example 35 | US20230365554, Example...)
Affinity DataIC50: 6.20nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636453((+)-(2R or S)—N-{4-[cis-3-anilino-4-oxo-1,4,5...)
Affinity DataIC50: 6.30nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636436(N-[4-(3-anilino-7-ethyl-4-oxo-4,5-dihydro-1H-pyrro...)
Affinity DataIC50: 6.40nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636449(US20230365554, Example 18 | US20230365554, Example...)
Affinity DataIC50: 6.5nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636437(N-{4-[3-anilino-5,7-dimethyl-4-oxo-4,5,6,7-tetrahy...)
Affinity DataIC50: 6.5nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636449(US20230365554, Example 18 | US20230365554, Example...)
Affinity DataIC50: 6.60nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636469(N-[4-(3-anilino-5,7-dimethyl-4-oxo-4,5-dihydro-1H-...)
Affinity DataIC50: 6.60nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
The Broad Institute

US Patent
LigandPNGBDBM636464(2-(4-fluorophenyl)-N-{4-[5-methyl-3-(2-methylanili...)
Affinity DataIC50: 7nMAssay Description:Recombinant fusion protein of N-terminal Glutathion-S-Transferase (GST) and a fragment of human EGFR (amino acids R669 to A1210), expressed in Sf9 in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636445(US20230365554, Example 14 | US20230365554, Example...)
Affinity DataIC50: 7.10nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636459(US20230365554, Example 28 | US20230365554, Example...)
Affinity DataIC50: 7.10nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636436(N-[4-(3-anilino-7-ethyl-4-oxo-4,5-dihydro-1H-pyrro...)
Affinity DataIC50: 7.20nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636477(US20230365554, Example 46 | US20230365554, Example...)
Affinity DataIC50: 7.5nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636466(US20230365554, Example 35 | US20230365554, Example...)
Affinity DataIC50: 7.60nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 7.70nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

Displayed 1 to 50 (of 180 total ) | Next | Last >>
Jump to: